Cholesterol absorption inhibitors in development as potential therapeutics

Area of Science:

• Pharmacology
• Gastroenterology
• Cardiovascular Disease

Background:

• Drugs acting in the gastrointestinal tract have been used for over 30 years to lower low-density lipoprotein cholesterol (LDL-C).
• Traditional bile acid sequestrants possess good safety profiles but limited clinical utility due to poor tolerability.
• Emerging gut-acting therapies demonstrate enhanced tolerability and superior LDL-C reduction compared to older agents.

Purpose of the Study:

• To review the advancements in gut-acting cholesterol-lowering drugs.
• To highlight novel therapeutic targets and their role in managing dyslipidemia and atherosclerotic vascular disease.

Main Methods:

• Review of clinical trials and scientific literature on gastrointestinal cholesterol-lowering agents.
• Analysis of the mechanisms of action for bile acid sequestrants, cholesterol absorption inhibitors, and bile acid transporter inhibitors.
• Exploration of emerging therapeutic targets within cholesterol absorption pathways.

Main Results:

• Newer bile acid sequestrants exhibit better tolerability and greater LDL-C reduction than older formulations.
• Cholesterol absorption inhibitors and bile acid transporter inhibitors show promising clinical efficacy and safety.
• Understanding cholesterol absorption mechanisms identifies new targets like the ATP-binding cassette transporter.

Conclusions:

• Gut-acting drugs represent a significant therapeutic strategy for lowering cholesterol.
• Novel agents and targets offer improved management of dyslipidemia and atherosclerotic vascular disease.
• Further research into cholesterol absorption pathways will yield advanced therapeutic options.